NE
Neuphoria Therapeutics Inc.
NEUP · NASDAQ
$3.35 -2.05% (-$0.07)
1M -10.67%
Market Cap $18.1M
P/E Ratio -
Div. Yield -
ROE 77.03%
Bulios Fair Price
$3.74
11.6% upside
Current Price
$3.35
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NEUP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/B 0.74x
P/S 15.42x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 1,088.56%
FCF growth N/A
EPS growth N/A
Profitability
17 /100
Weak Op. margin 1,187.73%
Gross margin 43.54%
FCF margin 1,052,120.00%
Quality
0 /100
Poor ROA 64.55%
ROIC 49.60%
Asset turnover 0.04x
Debt
100 /100
Low Current ratio 27.85x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
37 /100
Moderate Profitable years 0
Beta 0.75x
EPS volatility 691.22%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NEUP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Spyridon Papapetropoulos
Employees
1
Headquarters
Burlington